Anti-Human TL1A Monoclonal Antibody (Duvakitug)

Catalog Number: S0E0021 Application: ELISA Reactivity: Hu Conjugation: Unconjugated Brand: Starter

Price:

$445 USD

Size: 1mg

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Synonyms	Tumor necrosis factor ligand superfamily member 15; TNF ligand-related molecule 1; Vascular endothelial cell growth inhibitor; TL1; VEGI; TNFSF15
Location	Secreted
Accession	O95150
Antibody Type	Recombinant mAb
Application	ELISA
Reactivity	Hu
Purification	Protein A
Concentration	5 mg/ml
Endotoxin	<1EU/mg
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS pH7.4, containing no preservative
Stability & Storage	2 to 8 °C for 2 weeks under sterile conditions; -20 °C for 3 months under sterile conditions; -80 °C for 24 months under sterile conditions. Please avoid repeated freeze-thaw cycles.

Background

TL1A (also called TNFSF15, VEGI) is a 23-kDa type-II transmembrane cytokine of the TNF superfamily that forms homotrimers and is expressed by endothelial cells, monocytes, dendritic cells and fibroblasts; upon cleavage to soluble TL1A it binds chiefly to death receptor 3 (DR3/TNFRSF25) and, to a lesser extent, decoy receptor 3 (DcR3/TNFRSF6B), triggering TRADD/RIPK1/TRAF2-mediated activation of NF-κB and MAPK cascades that drive production of IFN-γ, TNF-α, IL-2, IL-5, IL-13 and IL-9, thereby amplifying Th1, Th2, Th9 and Th17 responses, enhancing NK-cell cytotoxicity, promoting dendritic-cell maturation and leukocyte chemotaxis, and, depending on context, inducing caspase-8/3-dependent apoptosis or necroptosis, while also inhibiting endothelial proliferation and angiogenesis; dysregulated TL1A is implicated in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, asthma and cancer, making it an attractive therapeutic target.